Join OncLive science summit on lung cancer with our oncology experts, Nov. 17

October 25, 2022 Providence Provider Update News Team

Share this Article
Facebook
Twitter
LinkedIn

Photo courtesy OncLive

PROVIDENCE CANCER INSTITUTE – Caregivers and providers are invited to join a free, in-person summit featuring some of our own oncology experts in downtown Portland.

OncLive, in partnership with Providence Cancer Institute, will host State of Science Summit: Lung Cancer on Nov. 17. OncLive is a leading digital provider of resources and information to oncology professionals.

This summit will cover new cancer treatment approaches, research and strategies. Featured speakers include Providence oncology experts Rachel Sanborn, M.D., Evelyn Brosnan, M.D., Regan M. Duffy, M.D., and Michael D. Skokan, M.D.

Dr. Sanborn, medical director, Providence Thoracic Oncology Program, will chair the event.

State of Science Summit: Lung Cancer
6-9 p.m.
Thursday, Nov. 17
The Benson Hotel
309 S.W. Broadway, Portland
Register online

Safety precautions will be implemented for the event, including single-use, disposable surgical masks available at check-in, social distancing measures for attendees, and a designated COVID compliance representative available to address any other personal protection concerns.

Learn more

For more details, go to event.onclive.com.

Providence St. Peter has new program in the fight against lung cancer

Ion robot-assisted bronchoscopy platform is first of its kind in South Puget Sound

Highly Respected Physician Named Executive Medical Director of the Leonard Cancer Institute at Providence Mission Hospital

James Bredenkamp, MD, a dedicated head and neck surgeon and skilled health care leader, has been named exec...

Other content in this Stream

Comprehensive Genomic Profiling leads to better patient outcomes, new joint study says  

Join OncLive science summit on lung cancer with our oncology experts, Nov. 17

Learn more

Previous Article

Next Article

Other content in this Stream

Real-world data from Providence, Illumina and Microsoft Research finds cancer patients with early genomic testing received better precision treatment, underlines urgency to become standard practice

R. Bryan Bell, M.D., D.D.S., FACS, FRCS(Ed) has accepted the roles of executive medical director of Providence Cancer Institute and director of the Earle A. Chiles Research Institute.

The annual SITC meeting brings together cancer immunotherapy researchers with a goal to advance science, discover breakthroughs and educate the world on cancer immunotherapy.

New study evaluates a type of CAR T-cell therapy called liso-cel. Researchers will collect data from multiple groups in a study that may give patients hope for long-term remission and quality of life.

Explore promising clinical trials at Providence Cancer Institute that are investigating immunotherapy for early-stage TNBC and high-risk, HR-positive breast cancer.

Providence Cancer Institute in partnership with AIM at Melanoma present a free online event designed to educate and empower patients and care partners affected by melanoma.

A new study approach reflects a deeper understanding of cancer at the molecular level and marks a shift away from one-size-fits-all treatments.

Dr. Allie Grossmann’s new lab at Earle A. Chiles Research Institute is focused on understanding how tumors communicate with their environment, grow, survive and spread.

Dr. Walter Urba, a pioneer and key figure in the development of immunotherapy, will retire from Providence Cancer Institute at the end of year.

Prominent cancer scientist Dr. Bernard Fox recognized for his work to advance the field of cancer immunotherapy through increasing public understanding, awareness and research efforts.

A new medication may help people with KRAS G12C-mutant non-small cell lung cancer. Read about the study and a trial evaluating an immunotherapy for treating head and neck squamous cell carcinoma.

Cancer survivor Mark Williams chats with Dr. Brendan Curti about

What motivates the co-captains of the FINISHCANCER caregiver team to commit their time to running this remarkable relay? Read what they say about preparing for the race and what inspires them to run.

Although chemotherapy is the cornerstone treatment for triple negative breast cancer, survival outcomes remain disappointing. Two studies could help improve treatment options.

A study designed to treat recurrent epithelial ovarian cancer looks at an antibody drug conjugate, and a second study for people with advanced breast cancer evaluates a drug that degrades estrogen rec

Providence Cancer Institute chief medical officer Walter J. Urba, M.D., Ph.D. talks about the evolution of immunotherapy in the past three decades and his vision for its future.

June is National Cancer Survivor Month, but we honor people with cancer, no matter where they are on their journey, every day of the year. Find out about the survivorship program at Providence Cancer

Providence Cancer Institute presented a free virtual education event about MRI-guided radiation therapy and how it is used to treat pancreatic cancer.

The annual meeting of cancer experts is a platform to collaborate and accelerate cancer research findings into clinical applications.

A joint study between Providence, Microsoft and the University of Washington detailing work to create a novel AI-powered pathology model has been published in Nature.